



(51) International Patent Classification:

C07D 215/38 (2006.01) A61K 31/502 (2006.01)
C07D 239/94 (2006.01) A61P 3/10 (2006.01)
A61K 31/47 (2006.01)

(21) International Application Number:

PCT/IB2012/053575

(22) International Filing Date:

12 July 2012 (12.07.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/510,582 22 July 2011 (22.07.2011) US
61/642,077 3 May 2012 (03.05.2012) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DIDIUK, Mary** [UA/US]; 61 Hickory Lane, Madison, Connecticut 06443 (US). **FILIPSKI, Kevin J.** [US/US]; 89 County Road,


Reading, Massachusetts 01867 (US). **GUZMAN-PEREZ, Angel** [MX/US]; 20 Gilmore Road, Belmont, Massachusetts 02478 (US). **LEE, Esther C.** [US/US]; 58C Peabody Road, Shirley, Massachusetts 01464 (US). **PFEFFERKORN, Jeffrey A.** [US/US]; 1 Nara Ridge Road, Acton, Massachusetts 01720 (US). **STEVENS, Benjamin** [US/US]; 100 Landsowne Street, Apt. 4, Cambridge, Massachusetts 02139 (US). **TU, Meihua** [US/US]; 6 Henley Road, Acton, Massachusetts 01720 (US).

(74) Agent: **OLSON, A. Dean**; Pfizer Inc., C/o Eastern Point Road, MS 2141, Groton, CT 06430 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: QUINOLINYL GLUCAGON RECEPTOR MODULATORS



(57) Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , A^1 , A^2 , A^3 , B^1 , B^2 , B^3 and B^4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))